Team Lake Ontario, or team Lake America? There’s a hat for both camps
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Lynx1 Capital Management LP, a 10% owner and director of Korro Bio, Inc. (), acquired common stock totaling $78,809 through two separate transactions in early August 2026. The purchases were made at weighted average prices ranging from $11.3998 to $13.1869 per share. The stock has delivered a 10% return over the past week and is up 67% year-to-date, though InvestingPro analysis suggests the shares are slightly overvalued at current levels near $13.59. According to InvestingPro Tips, the company holds more cash than debt on its balance sheet, one of 12 key insights available to subscribers.
On August 6, 2026, Lynx1 Capital Management LP purchased 5,222 shares of Korro Bio common stock at a weighted average price of $11.3998 per share. These shares were acquired in multiple transactions at prices ranging from $11.39 to $11.40 per share.
Subsequently, on August 10, 2026, the firm acquired an additional 1,462 shares of Korro Bio common stock at a weighted average price of $13.1869 per share. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 per share.
Following these transactions, Lynx1 Capital Management LP indirectly holds 1,544,980 shares of Korro Bio common stock. The securities are held directly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as the investment manager. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, is the general partner of the investment manager.
In other recent news, Korro Bio Inc. has announced the addition of KRRO-111 to its pipeline, aimed at treating alpha-1 antitrypsin deficiency (AATD). This new candidate is a GalNAc-conjugated oligonucleotide intended to repair a specific genetic variant, potentially restoring normal protein production. Meanwhile, analysts at Raymond James have reiterated their Outperform rating for Korro Bio, with a price target of $23.00, citing the company’s expansion into hyperammonemia indications. This includes plans for a first in-human clinical study for KRRO-121 by the second half of 2026, pending regulatory approval.
Additionally, H.C. Wainwright has adjusted its price target for Korro Bio to $15 from $20, while maintaining a Buy rating. The firm highlighted that the lead program KRRO-121 remains on track for a regulatory filing in the latter half of 2026. These developments underscore Korro Bio’s ongoing efforts in advancing its treatment programs for hyperammonemia and AATD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
